Trump administration target CDC for coronavirus investigation

Amy Baxter | | Health Exec | Management
COVID

As the number of COVID-19 cases in the United States continues to rise, surpassing 2.3 million cases as of June 23, the Trump administration is taking aim at the CDC as a possible scapegoat. The administration is reportedly weighing whether to launch an in-depth evaluation of the agency to find and highlight perceived missteps in the fight against the pandemic, Politico reported.

The investigation would focus on the state-by-state death toll to look at how many Americans died from COVID-119 directly, rather than other factors, according to the report, which was based on interviews with 10 current and former senior administration officials and White House Republicans.

Trump has already criticized the World Health Organization, promising to withdraw the U.S. from the international organization. However, creating a “boogeyman” out of the CDC to shift the blame of the COVID-19 response in the U.S. away from Trump may be more challenging, according to one former administration official cited in Politico’s story. Actions to criticize and blame career health officials could backfire.

A White House official told Politico after publication of its story that an investigation is not intended to mire the CDC, but ensuring data is accurate and verified.

See the full story below:

Trump team weighs a CDC scrubbing to deflect mounting criticism

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.